See more : Keypath Education International, Inc. (KED.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Annovis Bio, Inc. (ANVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Annovis Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Akzo Nobel N.V. (AKZA.AS) Income Statement Analysis – Financial Results
- SBC Exports Limited (SBC.NS) Income Statement Analysis – Financial Results
- WWPKG Holdings Company Limited (8069.HK) Income Statement Analysis – Financial Results
- HPC SYSTEMS Inc. (6597.T) Income Statement Analysis – Financial Results
- PATRIZIA SE (PAT.DE) Income Statement Analysis – Financial Results
Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| General & Administrative | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Other Expenses | 0.00 | 0.00 | -36.75K | -1.16M | -735.08K | 0.00 | 0.00 |
| Operating Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Cost & Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Interest Income | 667.90M | 182.71K | 13.34K | 47.23K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 47.23M | 0.00 | 66.00 | 84.00 |
| Depreciation & Amortization | 1.00 | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| EBITDA | -45.04M | 0.00 | 0.00 | 0.00 | 0.00 | 66.00 | 84.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.04M | -25.51M | -14.54M | -6.64M | -1.61M | -713.94K | -682.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66.00 | 84.00 |
| Income Before Tax | -56.20M | -25.33M | -14.49M | -5.46M | -990.98K | -713.87K | -682.35K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -182.71K | -50.09K | -1.20M | -694.14K | -132.00 | -682.43K |
| Net Income | -56.20M | -25.15M | -14.44M | -4.26M | -296.84K | -713.87K | -682.35K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| EPS Diluted | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
| Weighted Avg Shares Out (Dil) | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio's (NYSE: ANVS) recent feature on Today's Marketplace (TMP) as...
/C O R R E C T I O N -- Today's Marketplace/
In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the company that in the Annovis boilerplate, the first sentence should include the...
Annovis to Host Year-End Investor Webcast on December 11, 2024
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024,...
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part...
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease...
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition.”
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ),...
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder,...
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease...
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
Source: https://incomestatements.info
Category: Stock Reports